Resiquimod
Resiquimod has been studied in 3 papers since 2022: none in people yet, 2 in animals, 1 in cells; 1 in the past year. The research so far is in animals and cells. The newest paper, May 20, 2026: “Senescent Cell Derived Artificial Vesicle-Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross-Presentation Efficacy”.
See all 4 papers on resiquimod
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: National Center for Advancing Translational Sciences and 3 more
- Animals2
- Cells1
What did studies of resiquimod find?
2Studies of resiquimod measured 2 outcomes: virus-specific IgG antibody and virus-specific IgM antibody.
Virus-specific IgG antibody
upin C. aethiops1
1 study
Virus-specific IgG antibody
upin C. aethiops1
Resiquimod increases virus-specific IgG antibody in C. aethiops after boosting.
“there were significant increases in virus-specific IgG after boosting selectively in the IPR8-R848 vaccinated animals.”
Animalsafter boosting
Vaccines
Virus-specific IgM antibody
upin C. aethiops1
1 study
Virus-specific IgM antibody
upin C. aethiops1
Resiquimod increases virus-specific IgM antibody in C. aethiops.
“We observed increases in the level of circulating virus-specific IgM antibody 10 days following primary vaccination in AGM that were vaccinated with IPR8-R848, but not IPR8 alone.”
Animals10 days
Vaccines